MA54388A - Méthodes de traitement du cancer résistant aux inhibiteurs cdk4/6 - Google Patents

Méthodes de traitement du cancer résistant aux inhibiteurs cdk4/6

Info

Publication number
MA54388A
MA54388A MA054388A MA54388A MA54388A MA 54388 A MA54388 A MA 54388A MA 054388 A MA054388 A MA 054388A MA 54388 A MA54388 A MA 54388A MA 54388 A MA54388 A MA 54388A
Authority
MA
Morocco
Prior art keywords
cdk4
inhibitors
methods
treating cancer
cancer resistant
Prior art date
Application number
MA054388A
Other languages
English (en)
Inventor
Heike Arlt
Teeru Bihani
Hitisha Patel
Nianjun Tao
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of MA54388A publication Critical patent/MA54388A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA054388A 2018-12-06 2019-12-06 Méthodes de traitement du cancer résistant aux inhibiteurs cdk4/6 MA54388A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862776323P 2018-12-06 2018-12-06

Publications (1)

Publication Number Publication Date
MA54388A true MA54388A (fr) 2021-10-13

Family

ID=69063871

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054388A MA54388A (fr) 2018-12-06 2019-12-06 Méthodes de traitement du cancer résistant aux inhibiteurs cdk4/6

Country Status (17)

Country Link
US (2) US20210330612A1 (fr)
EP (1) EP3890834A1 (fr)
JP (1) JP7504097B2 (fr)
KR (1) KR20210100137A (fr)
CN (2) CN113164779A (fr)
AU (1) AU2019395093B2 (fr)
BR (1) BR112021010110A2 (fr)
CA (1) CA3121930A1 (fr)
EA (1) EA202191283A1 (fr)
IL (1) IL283659A (fr)
JO (1) JOP20210137B1 (fr)
MA (1) MA54388A (fr)
MX (1) MX2021006411A (fr)
PH (1) PH12021551319A1 (fr)
SG (1) SG11202105531XA (fr)
UA (1) UA130036C2 (fr)
WO (1) WO2020118213A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
WO2021041348A1 (fr) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Procédés de traitement du cancer du sein avec des dérivés de tétrahydronaphtalène en tant qu'agents de dégradation du récepteur des œstrogènes
IL303143A (en) * 2020-12-14 2023-07-01 Arvinas Operations Inc Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
GB202116745D0 (en) * 2021-11-19 2022-01-05 Institute Of Cancer Res Royal Cancer Hospital Prognostic and treatment response predictive method
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN116327894B (zh) * 2023-04-10 2026-05-29 上海市第一妇婴保健院 一种治疗kras突变的卵巢癌的组合药物及其应用
WO2025202871A1 (fr) * 2024-03-27 2025-10-02 Pfizer Inc. Procédés d'identification de biomarqueurs de réponse à un traitement et leur utilisation avec un inhibiteur de cdk4
CN121592777A (zh) * 2025-12-15 2026-03-03 中国医学科学院肿瘤医院 Pik3ca和esr1共突变在预测乳腺癌患者对吡洛西利和氟维司群联合治疗敏感性中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
MX384605B (es) * 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
EP3565542B1 (fr) * 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Formes polymorphes de rad1901-2hcl
SG11202013177WA (en) * 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl

Also Published As

Publication number Publication date
KR20210100137A (ko) 2021-08-13
JP2022511498A (ja) 2022-01-31
EP3890834A1 (fr) 2021-10-13
CN113164779A (zh) 2021-07-23
JOP20210137A1 (ar) 2023-01-30
US20210330612A1 (en) 2021-10-28
UA130036C2 (uk) 2025-10-22
AU2019395093B2 (en) 2025-01-23
CN119548484A (zh) 2025-03-04
CA3121930A1 (fr) 2020-06-11
PH12021551319A1 (en) 2022-05-16
US20250319044A1 (en) 2025-10-16
WO2020118213A1 (fr) 2020-06-11
EA202191283A1 (ru) 2021-10-13
JOP20210137B1 (ar) 2025-10-01
IL283659A (en) 2021-07-29
SG11202105531XA (en) 2021-06-29
JP7504097B2 (ja) 2024-06-21
MX2021006411A (es) 2021-07-21
BR112021010110A2 (pt) 2021-08-24
AU2019395093A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
EP3423488A4 (fr) Méthodes de traitement du cancer
EP3478286A4 (fr) Méthodes de traitement du cancer de l'ovaire
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
EP3426271A4 (fr) Méthodes de traitement de tumeurs solides ou lymphatiques par polythérapie
EP3288383A4 (fr) Méthodes de traitement du cancer
IL283659A (en) Methods for treating cancer resistant to cdk4/6 inhibitors
MA56212A (fr) Compositions et méthodes de traitement du cancer
EP3506944A4 (fr) Compositions et méthodes de traitement d'un cancer déficient en suppresseurs tumoraux
EP3405203A4 (fr) Méthodes de traitement du cancer
EP3820461A4 (fr) Méthode de traitement du cancer
EP3589659A4 (fr) Composés et méthodes de traitement du cancer
EP3440112A4 (fr) Méthodes de traitement du cancer
EP3778649A4 (fr) Méthode et composition de traitement de tumeurs
EP3389634A4 (fr) Méthodes de traitement du cancer
EP3801768A4 (fr) Méthodes de traitement de troubles du hyperprolifératifs malins
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3389652A4 (fr) Méthodes de traitement du cancer
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
EP3787625A4 (fr) Méthodes de traitement du cancer
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3298141A4 (fr) Compositions et méthodes de traitement du cancer
EP3852816A4 (fr) Méthodes de traitement de cancer